Mr Nicholson has over 40 years international experience in management and transactions within the life sciences sector. He has extensive Board experience in public and private companies and is currently Chairman of Bioventix plc, where he was appointed in 2004, a Board Trustee of LifeArc, a leading UK medical research charity and Chairman, Aleta Biotherapeutics UK Limited.He has been an Operating Partner at Advent Life Sciences LLP since 2012, working with portfolio companies including Eloxx Pharmaceuticals, Amphista and NeRRe Therapeutics.From 2013 to 2021, Mr Nicholson was CEO of F2G Ltd., an antifungal drug development company and from 2004 to 2012 he was CEO of Chroma Therapeutics Limited, a drug discovery and development company.